#None #Theravance Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma's Financial and Operational Update for Q3 2025

On November 10, 2025, Theravance Biopharma, Inc. announced its financial results for the third quarter of 2025, showcasing substantial growth and a promising outlook in the biotechnology sector. The company reported an impressive $71.4 million in net sales for YUPELRI®, a medication recognized for its effectiveness in treating chronic obstructive pulmonary disease (COPD). This figure marks a remarkable 15% increase compared to the previous year, demonstrating strong customer demand and effective pricing strategies.

Key Financial Highlights

Theravance achieved a notable milestone by reaching breakeven on a non-GAAP basis, reflecting a disciplined approach to both financial and operational management, as emphasized by CEO Rick E Winningham. The company’s strong balance sheet features $333 million in cash and no debt, providing a solid foundation for future growth initiatives.

The quarter saw the completion of the open-label portion of the pivotal Phase 3 CYPRESS study regarding ampreloxetine, an investigational treatment for neurogenic orthostatic hypotension in patients with multiple system atrophy. Topline results are expected in the first quarter of 2026.

Robust Product Performance

YUPELRI

YUPELRI, a once-daily nebulized long-acting muscarinic antagonist (LAMA), continues to set benchmarks in treating COPD. In Q3 2025, the product's sales surged owing to a 6% rise in customer demand year-over-year and beneficial changes in pricing strategies. Significant improvements in sales through hospital channels, which increased by 29% compared to the previous year, contribute to these impressive figures.

Theravance aims to achieve a $250 million net sales target for 2025, with about $54 million needed in the last quarter to trigger a $25 million milestone.

Ampreloxetine

In addition to YUPELRI, Theravance is advancing its potential blockbuster drug, ampreloxetine. The completion of patient enrollment in the CYPRESS trial is a vital step toward introducing this medication, which aims to address a significant unmet need in patients suffering from neurogenic orthostatic hypotension associated with MSA. On December 8, 2025, Theravance will host a virtual Key Opinion Leader event, where healthcare professionals will discuss the drug's potential impact.

Research and Development Focus

The company's R&D expenses for the third quarter were reported at $8.1 million, showing a slight decrease from $9.3 million in Q3 2024. This indicates a focused investment in advancing drug development while optimizing resource allocation. Additionally, clinical presentations at significant medical conferences have solidified its standing in the industry.

Looking Ahead

For the remainder of 2025, Theravance Biopharma projects its R&D expenses to range between $32 million to $38 million, alongside SGA expenses expected to be between $50 million to $60 million. As the company progresses, maintaining operational discipline remains essential, with expectations of remaining at breakeven non-GAAP margins in Q4.

The formation of a Strategic Review Committee signifies Theravance's commitment to exploring avenues to enhance shareholder value, further emphasizing its intention to utilize excess cash effectively.

In summary, Theravance Biopharma's reporting confirms a robust trajectory of growth, driven by successful product sales and a strong pipeline, promising substantial value for patients and investors alike as the company continues to navigate the complexities of the biopharmaceutical landscape.